Citi reiterates Sell rating on Sarepta stock amid FDA concerns

Sarepta Therapeutics (SRPT) faces severe regulatory challenges for its gene therapy Elevidys, leading Citi to reiterate a Sell rating and a $7.00 price target, following a 91% stock decline over the past year. The FDA's CBER reviewers unanimously agreed Elevidys should not return to market without new studies, citing a clear connection between three patient fatalities and liver toxicity, which contradicts Sarepta's prior claims. The company has voluntarily suspended U.S. shipments to update the label, expected to include a black box warning, while multiple analysts have downgraded the stock and revised earnings estimates downward due to significant safety concerns and forward risks.

Analysis

Sarepta Therapeutics (SRPT) is confronting a severe crisis regarding its gene therapy, Elevidys, which has precipitated a more than 91% decline in its stock value over the past year. The primary catalyst is a unanimous recommendation from the FDA's Center for Biologics Evaluation and Research (CBER) reviewers that Elevidys should not return to the market without new studies to validate its safety profile. This regulatory stance is underpinned by significant safety concerns, with FDA officials reportedly identifying a direct link between three patient fatalities and liver toxicity, a conclusion that contradicts Sarepta's prior assertions. In response, the company has voluntarily suspended U.S. shipments to add a black box warning for acute liver injury. The negative sentiment is echoed across the analyst community, with Citi reiterating a Sell rating and a $7.00 price target, initiating a 90-day downside catalyst watch, and eight analysts revising earnings estimates downward. Freedom Broker has also downgraded the stock to Hold. The confluence of these regulatory roadblocks, critical safety issues, and eroding analyst confidence raises substantial questions about the viability of Elevidys and the credibility of company management.

Key Decisions for Investors

• Given the unanimous negative recommendation from FDA reviewers and unresolved safety signals linking Elevidys to patient fatalities, investors should view SRPT as carrying extremely high regulatory and clinical risk.
• The stock's current price of $12.88 remains significantly above Citi's $7.00 target, suggesting further downside potential, and any long position should be considered highly speculative pending a complete and unlikely reversal of the FDA's stance.
• Investors should monitor for official FDA communication regarding the new black box warning and any company announcements on plans for new clinical trials, as these will be critical determinants of the asset's future.
• The discrepancy between the company's and the FDA's assessment of patient fatalities raises significant management credibility concerns that must be factored into any investment thesis.